ClinicalTrials.gg
CompletedNCT02275117Updated Apr 8, 2020Results posted

A Multicenter Assessment of ALD403 in Chronic Migraine

A Phase 2 interventional study of ALD403 and Placebo in Migraine Disorders, sponsored by Alder Biopharmaceuticals, Inc.. Completed at 92 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-04-08.

Sponsored by Alder Biopharmaceuticals, Inc. (part of H. Lundbeck A/S) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
665
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
5th of 21
665 · median 193
Started
2014
the only one that year
Phase 2
Only one
of the 21
Registered
3rd of 21
by date
Lead sponsor
6 of 21
Alder Biopharmaceuticals, Inc.

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 5th largest by enrollment, is the only one that started in 2014, is the only one in phase 2, and was the 3rd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.

03

Conditions studied

  • Migraine Disorders

Browse trials for

Keywords

  • Migraine Disorders
  • ALD403
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of migraine at ≤ 35 years of age with history of chronic migraine ≥ 1 year
  • During the 28 day screening period, must have ≥ 15 headache days of which ≥ 8 days were assessed as migraine days with at least 5 migraine attacks as recorded in the eDiary
  • Headache eDiary was completed on at least 22 of the 28 days prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Confounding pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome) or any pain syndrome that requires regular analgesia
  • Psychiatric conditions that are uncontrolled and untreated, including conditions that are not controlled for a minimum of 6 months prior to screening.
  • History or diagnosis of complicated migraine (ICHD-III beta version, 2013), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, migraine with brainstem aura, sporadic and familial hemiplegic migraine
  • Unable to differentiate migraine from other headaches
  • Subject has received botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections in the head, face, or neck within 4 months prior to screening.
  • Have any concurrent medical condition
  • Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial)
  • Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
665 participants (actual)

Study arms

  • Experimental
    ALD403 Dose Level 1

    ALD403 Dose Level 1 (IV)

    Biological: ALD403

  • Experimental
    ALD403 Dose Level 2

    ALD403 Dose Level 2 (IV)

    Biological: ALD403

  • Experimental
    ALD403 Dose Level 3

    ALD403 Dose Level 3 (IV)

    Biological: ALD403

  • Experimental
    ALD403 Dose Level 4

    ALD403 Dose Level 4 (IV)

    Biological: ALD403

  • Placebo comparator
    Placebo

    Placebo (IV)

    Biological: Placebo

Interventions

  • BiologicalALD403

    Also known as: Eptinezumab-jjmr, Vyepti

  • BiologicalPlacebo
06

What researchers measure

Primary outcomes

  1. 75% Migraine Responder Rate

    Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.

    Time frame: 12 Weeks

Secondary outcomes

  1. 50% Migraine Responder Rate

    Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline

    Time frame: Weeks 1-12

  2. 50% Headache Responder Rate

    Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline

    Time frame: Weeks 1-12

  3. 100% Headache Responder Rate

    Participants with an average reduction in headache days of at least 100% over Weeks 1 to 12, as compared with baseline

    Time frame: Weeks 1-12

  4. 100% Migraine Responder Rate

    Participants with an average reduction in migraine days of at least 100% over Weeks 1 to 12, as compared with baseline

    Time frame: Weeks 1-12

  5. The Change From Baseline in Monthly Headache Days, Weeks 1-12

    Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.

    Time frame: Weeks 1-12

  6. The Change From Baseline in Monthly Migraine Days, Weeks 1-12

    Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.

    Time frame: Weeks 1-12

  7. Change From Baseline in Percentage of Severe Migraines

    The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12

    Time frame: Weeks 1-12

  8. Change From Baseline in Percentage of Severe Headaches

    The change from baseline in percentage of headaches that are classified as severe over Weeks 9-12

    Time frame: Weeks 9-12

  9. The Change From Baseline to Week 12 in HIT-6 Total Score

    The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). A score of 60 or above is labeled as "severe".

    Time frame: Baseline to 12

  10. Percent Change From Baseline in Headache Days

    Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.

    Time frame: Weeks 1-12

  11. Percent Change From Baseline in Migraine Days

    Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.

    Time frame: Weeks 1-12

  12. Time to First Migraine After Dosing

    The median number of days after dosing a participant had the next migraine using the eDiary as the recall method

    Time frame: Baseline to Week 49 (End of Study)

  13. Change From Baseline in Monthly Migraine Attacks, Weeks 1-12

    The number of monthly migraine attacks summarized over Weeks 1-12. A migraine attack is defined as 1 continuously recorded migraine. One attack may result in multiple migraine days

    Time frame: Weeks 1-12

  14. Change From Baseline in Monthly Headache Episodes, Weeks 1-12

    The number of monthly headache episodes as summarized over Weeks 1-12. A headache episode is defined as 1 continuously recorded headache. One episode may result in multiple headache days

    Time frame: Weeks 1-12

  15. Change From Baseline in Monthly Migraine Hours, Weeks 1-12

    Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.

    Time frame: Weeks 1-12

  16. Change From Baseline in Monthly Headache Hours, Weeks 1-12

    Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.

    Time frame: Weeks 1-12

  17. Change From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication

    The percent of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.

    Time frame: Weeks 9-12

  18. Change From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication

    The percent of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.

    Time frame: Weeks 9-12

  19. Baseline and Change From Baseline in Short Form Health Survey (SF-36, Version 2.0) at Week 12

    The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (range: 0=worst to 100=best). Increases from baseline indicate improvement.

    Time frame: Baseline to Week 12

07

Results

Posted Mar 30, 2020

Participant flow

Participant flow — Overall Study
Milestone300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Started131133134133134
Randomized and treated120123122130121
Completed97969210098
Not completed3437423336
Withdrew: Adverse event00001
Withdrew: Lack of efficacy675210
Withdrew: Lost to follow-up111615168
Withdrew: Physician decision01101
Withdrew: Protocol violation10110
Withdrew: Withdrawal by subject64733
Withdrew: Terminated by sponsor44464
Withdrew: Worsening of study indication01200
Withdrew: Study burden54757
Withdrew: Other10002

Outcome measures

Primary75% Migraine Responder Rate

Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.

Time frame:
12 Weeks
Reported as:
Count of participants · Participants
75% Migraine Responder Rate
Participants300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
75% Migraine Responder Rate3837333324
Statistical analysis
  • 300 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = 0.0330 · Mean difference (final values): 12.6 · 95% CI 1.3 to 24.0
  • 100 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = 0.0715 · Mean difference (final values): 10.7 · 95% CI -0.5 to 21.8
  • 30 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = 0.2013 · Mean difference (final values): 7.5 · 95% CI -3.5 to 18.5
  • 10 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = 0.2938 · Mean difference (final values): 6.1 · 95% CI -4.6 to 16.9
Secondary50% Migraine Responder Rate

Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline

Time frame:
Weeks 1-12
Reported as:
Count of participants · Participants
50% Migraine Responder Rate
Participants300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
50% Migraine Responder Rate6565655447
Secondary50% Headache Responder Rate

Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline

Time frame:
Weeks 1-12
Reported as:
Count of participants · Participants
50% Headache Responder Rate
Participants300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
50% Headache Responder Rate5955554839
Secondary100% Headache Responder Rate

Participants with an average reduction in headache days of at least 100% over Weeks 1 to 12, as compared with baseline

Time frame:
Weeks 1-12
Reported as:
Count of participants · Participants
100% Headache Responder Rate
Participants300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
100% Headache Responder Rate40011
Secondary100% Migraine Responder Rate

Participants with an average reduction in migraine days of at least 100% over Weeks 1 to 12, as compared with baseline

Time frame:
Weeks 1-12
Reported as:
Count of participants · Participants
100% Migraine Responder Rate
Participants300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
100% Migraine Responder Rate965103
SecondaryThe Change From Baseline in Monthly Headache Days, Weeks 1-12

Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.

Time frame:
Weeks 1-12
Reported as:
Mean · days
The Change From Baseline in Monthly Headache Days, Weeks 1-12
days300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
The Change From Baseline in Monthly Headache Days, Weeks 1-12-9.6 ± 6.94-8.9 ± 6.79-9.2 ± 6.33-7.5 ± 6.93-6.9 ± 6.37
SecondaryThe Change From Baseline in Monthly Migraine Days, Weeks 1-12

Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.

Time frame:
Weeks 1-12
Reported as:
Mean · days
The Change From Baseline in Monthly Migraine Days, Weeks 1-12
days300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
The Change From Baseline in Monthly Migraine Days, Weeks 1-12-8.2 ± 7.00-7.7 ± 6.87-7.9 ± 6.38-6.7 ± 6.80-5.6 ± 6.56
SecondaryChange From Baseline in Percentage of Severe Migraines

The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12

Time frame:
Weeks 1-12
Reported as:
Mean · percentage of severe migraines
Change From Baseline in Percentage of Severe Migraines
percentage of severe migraines300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Change From Baseline in Percentage of Severe Migraines-20.7 ± 29.47-15.9 ± 27.38-17.2 ± 26.98-16.1 ± 29.80-9.7 ± 27.32
SecondaryChange From Baseline in Percentage of Severe Headaches

The change from baseline in percentage of headaches that are classified as severe over Weeks 9-12

Time frame:
Weeks 9-12
Reported as:
Mean · percentage of severe headaches
Change From Baseline in Percentage of Severe Headaches
percentage of severe headaches300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Change From Baseline in Percentage of Severe Headaches-19.91 ± 25.800-10.36 ± 28.004-12.17 ± 30.197-11.42 ± 30.517-6.48 ± 27.211
SecondaryThe Change From Baseline to Week 12 in HIT-6 Total Score

The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). A score of 60 or above is labeled as "severe".

Time frame:
Baseline to 12
Reported as:
Number · percentage of HIT-6 total score
The Change From Baseline to Week 12 in HIT-6 Total Score
percentage of HIT-6 total score300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
The Change From Baseline to Week 12 in HIT-6 Total Score-60.4-43.4-34.9-34.8-28.4
SecondaryPercent Change From Baseline in Headache Days

Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.

Time frame:
Weeks 1-12
Reported as:
Mean · percentage of headache days
Percent Change From Baseline in Headache Days
percentage of headache days300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Percent Change From Baseline in Headache Days-46.12 ± 31.481-43.09 ± 33.912-44.37 ± 28.620-37.20 ± 34.112-34.02 ± 30.970
SecondaryPercent Change From Baseline in Migraine Days

Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.

Time frame:
Weeks 1-12
Reported as:
Mean · percentage of migraine days
Percent Change From Baseline in Migraine Days
percentage of migraine days300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Percent Change From Baseline in Migraine Days-48.88 ± 41.243-46.79 ± 40.983-46.74 ± 36.588-40.80 ± 40.133-35.37 ± 41.100
SecondaryTime to First Migraine After Dosing

The median number of days after dosing a participant had the next migraine using the eDiary as the recall method

Time frame:
Baseline to Week 49 (End of Study)
Reported as:
Number · Days
Time to First Migraine After Dosing
Days300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Time to First Migraine After Dosing4.0 (3.0 to 5.0)4.0 (3.0 to 5.0)3.0 (2.0 to 5.0)4.0 (3.0 to 5.0)2.0 (1.0 to 3.0)
SecondaryChange From Baseline in Monthly Migraine Attacks, Weeks 1-12

The number of monthly migraine attacks summarized over Weeks 1-12. A migraine attack is defined as 1 continuously recorded migraine. One attack may result in multiple migraine days

Time frame:
Weeks 1-12
Reported as:
Mean · Migraine Attacks
Change From Baseline in Monthly Migraine Attacks, Weeks 1-12
Migraine Attacks300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Change From Baseline in Monthly Migraine Attacks, Weeks 1-12-6.8 ± 5.4-6.5 ± 4.9-6.9 ± 5.0-6.2 ± 5.2-5.5 ± 5.0
SecondaryChange From Baseline in Monthly Headache Episodes, Weeks 1-12

The number of monthly headache episodes as summarized over Weeks 1-12. A headache episode is defined as 1 continuously recorded headache. One episode may result in multiple headache days

Time frame:
Weeks 1-12
Reported as:
Mean · Headache Episodes
Change From Baseline in Monthly Headache Episodes, Weeks 1-12
Headache Episodes300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Change From Baseline in Monthly Headache Episodes, Weeks 1-12-8.2 ± 5.54-8.0 ± 5.37-8.3 ± 5.55-7.3 ± 5.37-7.0 ± 5.13
SecondaryChange From Baseline in Monthly Migraine Hours, Weeks 1-12

Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.

Time frame:
Weeks 1-12
Reported as:
Mean · Migraine Hours
Change From Baseline in Monthly Migraine Hours, Weeks 1-12
Migraine Hours300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Change From Baseline in Monthly Migraine Hours, Weeks 1-12-70.9 ± 100.34-64.2 ± 114.58-63.1 ± 84.56-49.2 ± 103.83-34.9 ± 100.87
SecondaryChange From Baseline in Monthly Headache Hours, Weeks 1-12

Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.

Time frame:
Weeks 1-12
Reported as:
Mean · Headache Hours
Change From Baseline in Monthly Headache Hours, Weeks 1-12
Headache Hours300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Change From Baseline in Monthly Headache Hours, Weeks 1-12-73.9 ± 101.53-60.9 ± 114.77-62.9 ± 81.89-47.5 ± 102.84-38.7 ± 99.26
SecondaryChange From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication

The percent of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.

Time frame:
Weeks 9-12
Reported as:
Mean · percentage of acute medication migraines
Change From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication
percentage of acute medication migraines300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Change From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication-15.43 ± 39.121-10.36 ± 43.890-4.44 ± 37.746-10.03 ± 40.460-9.60 ± 37.451
SecondaryChange From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication

The percent of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.

Time frame:
Weeks 9-12
Reported as:
Mean · percentage of acute medication headaches
Change From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication
percentage of acute medication headaches300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Change From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication-5.98 ± 34.144-3.27 ± 34.4191.52 ± 30.013-3.14 ± 32.853-3.42 ± 32.890
SecondaryBaseline and Change From Baseline in Short Form Health Survey (SF-36, Version 2.0) at Week 12

The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (range: 0=worst to 100=best). Increases from baseline indicate improvement.

Time frame:
Baseline to Week 12
Reported as:
Mean · SF-36 Score
Baseline and Change From Baseline in Short Form Health Survey (SF-36, Version 2.0) at Week 12
SF-36 Score300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Physical Functioning - Baseline50.5 ± 8.750.6 ± 7.851.1 ± 7.650.3 ± 8.450.2 ± 6.5
Physical Functioning - Week 1253.6 ± 5.051.2 ± 8.352.5 ± 7.251.3 ± 7.951.9 ± 6.1
Role Physical - Baseline43.9 ± 9.545.2 ± 9.345.6 ± 9.344.9 ± 9.944.3 ± 9.6
Role Physical - Week 1250.9 ± 7.248.9 ± 9.349.9 ± 7.747.9 ± 9.948.5 ± 8.3
Bodily Pain -Baseline42.7 ± 9.542.7 ± 9.644.5 ± 9.943.0 ± 9.642.5 ± 9.4
Bodily Pain - Week 1248.9 ± 8.446.5 ± 9.948.1 ± 9.246.6 ± 9.346.0 ± 9.5
General Health - Baseline50.4 ± 9.250.7 ± 9.850.9 ± 8.751.1 ± 9.550.7 ± 9.8
General Health - Week 1251.8 ± 8.750.7 ± 10.250.7 ± 9.252.7 ± 9.850.6 ± 10.0
Vitality - Baseline48.3 ± 8.950.1 ± 10.649.6 ± 9.849.4 ± 10.148.1 ± 10.9
Vitality - Week 1251.3 ± 7.850.9 ± 10.550.6 ± 11.350.7 ± 10.651.1 ± 10.2
Social Functioning - Baseline45.0 ± 10.846.3 ± 10.146.8 ± 10.745.5 ± 10.445.4 ± 10.3
Social Functioning - Week 1250.5 ± 8.148.7 ± 10.149.5 ± 9.047.7 ± 9.848.1 ± 8.7
Role Emotional - Baseline50.2 ± 9.149.4 ± 9.649.4 ± 9.749.8 ± 10.350.9 ± 8.1
Role Emotional - Week 1251.4 ± 8.250.2 ± 9.051.2 ± 7.250.9 ± 8.451.0 ± 8.3
Mental Health - Baseline51.4 ± 8.452.0 ± 9.351.8 ± 9.551.4 ± 9.550.8 ± 9.8
Mental Health - Week 1252.1 ± 8.850.8 ± 10.151.2 ± 9.552.2 ± 9.552.4 ± 8.8
Mental Component Score - Baseline50.4 ± 9.450.9 ± 9.750.5 ± 9.650.4 ± 9.950.5 ± 9.0
Mental Component Score - Week 1251.2 ± 9.050.5 ± 9.750.7 ± 9.451.3 ± 9.351.5 ± 8.9
Physical Component Score - Baseline45.5 ± 8.446.1 ± 8.447.1 ± 7.746.1 ± 8.345.5 ± 7.9
Physical Component Score - Week 1251.2 ± 6.849.0 ± 8.650.1 ± 7.048.8 ± 8.548.4 ± 8.1

Adverse events

Collected over Baseline to Week 49 (end of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
300 mg ALD4030/121 (0%)7/121 (5.8%)40/121 (33.1%)
100 mg ALD4030/122 (0%)4/122 (3.3%)38/122 (31.1%)
30 mg ALD4030/122 (0%)0/122 (0%)26/122 (21.3%)
10 mg ALD4030/130 (0%)1/130 (0.8%)35/130 (26.9%)
Placebo0/121 (0%)1/121 (0.8%)37/122 (30.3%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
Event300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Gastroenteritis viralInfections and infestations1/1210/1220/1220/1300/121
Vaginal abscessInfections and infestations1/1210/1220/1220/1300/121
ConcussionInjury, poisoning and procedural complications1/1210/1220/1220/1300/121
Head injuryInjury, poisoning and procedural complications1/1210/1220/1220/1300/121
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1211/1220/1220/1300/121
ConvulsionNervous system disorders1/1210/1220/1220/1300/121
Serotonin syndromeNervous system disorders1/1210/1220/1220/1300/121
Suicidal ideationPsychiatric disorders0/1210/1220/1221/1301/121
Pelvic painRenal and urinary disorders1/1210/1220/1220/1300/121
Respiratory distressReproductive system and breast disorders1/1210/1220/1220/1300/121
Most frequent other events
Most frequent other events
Event300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403Placebo
Upper respiratory tract infectionInfections and infestations13/1218/1227/1229/1306/122
DizzinessNervous system disorders2/12112/1223/12211/1309/122
NasopharyngitisInfections and infestations9/1218/1223/1226/1306/122
NauseaGastrointestinal disorders8/1219/1224/1226/1309/122
BronchitisInfections and infestations4/1214/1224/1224/1309/122
SinusitisInfections and infestations8/1213/1226/1228/1306/122
MigraineNervous system disorders1/1217/1223/1222/1302/122
Urinary tract infectionInfections and infestations6/1213/1221/1224/1305/122

Baseline characteristics

Safety population includes all subjects who received investigational product or placebo. 3 participants received duplicate randomization, participants are summarized within treatment group for which they actually received treatment.

Age, Continuous
Age, Continuous(years)300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403PlaceboTotal
Mean37.2 ± 10.036.7 ± 9.435.7 ± 9.436.4 ± 10.337.2 ± 9.236.6 ± 19.7
Sex: Female, Male
Sex: Female, Male(Participants)300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403PlaceboTotal
Female98104111113109535
Male231811171281
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403PlaceboTotal
Hispanic or Latino1823172716101
Not Hispanic or Latino10399105103105515
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403PlaceboTotal
American Indian or Alaska Native001214
Asian100113
Native Hawaiian or Other Pacific Islander001001
Black or African American4121412749
White114108103113109547
More than one race000000
Unknown or Not Reported2232312
Region of Enrollment
Region of Enrollment(participants)300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403PlaceboTotal
New Zealand7101211
United States10110610711599528
Georgia1191491558
Australia2615519
Baseline Migraine Days
Baseline Migraine Days(Participants)300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403PlaceboTotal
< 20 days8485879084430
≥ 20 days3737354037186
Medication Overuse Status
Medication Overuse Status(Participants)300 mg ALD403100 mg ALD40330 mg ALD40310 mg ALD403PlaceboTotal
No5662576457296
Yes6560656664320
08

Study locations

92 sites
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Phoenix, Arizona 85027, United States
  • Research Site
    Scottsdale, Arizona 85259, United States
  • Research Site
    Hot Springs, Arkansas 71901, United States
  • Research Site
    Little Rock, Arkansas 72211, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Encino, California 91436, United States
  • Reserach Site
    Long Beach, California 90806, United States
  • Research Site
    Los Angeles, California 90036, United States
  • Research Site
    Oakland, California 94612, United States
  • Research Site
    San Diego, California 92108, United States
  • Research Site
    San Francisco, California 94102, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Ventura, California 93003, United States
  • Research Site
    Colorado Springs, Colorado 80918, United States
  • Research Site
    Denver, Colorado 80210, United States
  • Research Site
    Stamford, Connecticut 06905, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Gainesville, Florida 32607, United States
  • Research Site
    Hallandale Beach, Florida 33009, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    North Miami, Florida 33161, United States
  • Research Site
    Orlando, Florida 32801, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Tampa, Florida 33606, United States
  • Research Site
    Atlanta, Georgia 30022, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Chicago, Illinois 60607, United States
  • Research Site
    Chicago, Illinois 60640, United States
  • Research Site
    Evansville, Illinois 47714, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Prairie Village, Kansas 66206, United States
  • Research Site
    Wichita, Kansas 67207, United States
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    New Orleans, Louisiana 70115, United States
  • Research Site
    Shreveport, Louisiana 71105, United States
  • Research Site
    Boston, Massachusetts 21310, United States
  • Research Site
    Brockton, Massachusetts 02301, United States
  • Research Site
    New Bedford, Massachusetts 02740, United States
  • Research Site
    Watertown, Massachusetts 02472, United States
  • Research Site
    Ann Arbor, Michigan 48104, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Springfield, Missouri 65807, United States
  • Research Site
    Omaha, Nebraska 68134, United States
  • Research Site
    Princeton, New Jersey 08540, United States
  • Research Site
    Albuquerque, New Mexico 87102, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    Amherst, New York 14226, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    Brooklyn, New York 11235, United States
  • Research Site
    Endwell, New York 13760, United States
  • Research Site
    New York, New York 10019, United States
  • Research Site
    Rochester, New York 14609, United States
  • Research Site
    Cary, North Carolina 27518, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Canton, Ohio 44718, United States
  • Research Site
    Cincinnati, Ohio 45255, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Columbus, Ohio 43213, United States
  • Research Site
    Dayton, Ohio 45424, United States
  • Research Site
    Oklahoma City, Oklahoma 73116, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Willow Grove, Pennsylvania 19090, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Chattanooga, Tennessee 37421, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Austin, Texas 78705, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77058, United States
  • Research Site
    Orem, Utah 84058, United States
  • Research Site
    Salt Lake City, Utah 84109, United States
  • Research Site
    Richmond, Virginia 23226, United States
  • Research Site
    Virginia Beach, Virginia 23454, United States
  • Research Site
    Bellevue, Washington 98007, United States
  • Research Site
    Seattle, Washington 98105, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Sydney, New South Wales 2031, Australia
  • Research Site
    Melbourne, Victoria 3004, Australia
  • Research Site
    Melbourne, Victoria 3050, Australia
  • Research Site
    Perth, Western Australia 6009, Australia
  • Research Site
    Tbilisi, 0112, Georgia
  • Research Site
    Tbilisi, 0160, Georgia
  • Research Site
    Tbilisi, 0186, Georgia
  • Research Site
    Auckland, 8963, New Zealand
  • Research Site
    Christchurch, 2856, New Zealand
  • Research Site
    Hamilton, 3204, New Zealand
09

References and documents

Publications

  • Smith TR, Spierings ELH, Cady R, Hirman J, Ettrup A, Shen V. Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies. J Headache Pain. 2021 Nov 25;22(1):143. doi: 10.1186/s10194-021-01360-1. PubMed 34823467 ↗
  • Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V, Sperling B, Brevig T, Josiassen MK, Brunner E, Honeywell L, Mehta L. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021 Mar 30;22(1):16. doi: 10.1186/s10194-021-01227-5. Erratum In: J Headache Pain. 2021 May 25;22(1):46. doi: 10.1186/s10194-021-01253-3. PubMed 33781209 ↗
  • Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24. PubMed 31234642 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Mar 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2020, 4 years after primary completion. A results delay was requested in Sep 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2014
First posted
Oct 27, 2014
Start
Oct 2014
Primary completionActual
Mar 2016
CompletionActual
Nov 2016
Results delay requested
Sep 18, 2018
Results first posted
Mar 30, 2020
Last update
Apr 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02275117
Responsible party
Sponsor
First posted
Oct 27, 2014
Start date
Oct 2014
Primary completion
Mar 2016
Completion
Nov 2016
Results posted
Mar 30, 2020
Last update
Apr 8, 2020

Study contacts

Jeff TL Smith, MD
study director · Alder Biopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion